Black Diamond Therapeutics, Inc.

NasdaqGS:BDTX Stock Report

Market Cap: US$116.1m

Black Diamond Therapeutics Past Earnings Performance

Past criteria checks 0/6

Black Diamond Therapeutics has been growing earnings at an average annual rate of 34.3%, while the Biotechs industry saw earnings growing at 34.1% annually. Revenues have been growing at an average rate of 70.9% per year.

Key information

34.31%

Earnings growth rate

41.39%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate70.92%
Return on equity-44.29%
Net Marginn/a
Last Earnings Update30 Jun 2026

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Jul 06

Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside

Summary Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in precision oncology. Silevertinib, BDTX’s lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR, targeting NSCLC patients underserved by legacy TKIs. Despite mega-cap competition, BDTX’s $118M cash runway, potential non-dilutive milestone payments, and MasterKey platform underpin a Buy rating. Risk-adjusted valuation suggests a fair value of $6.64/share, over 200% above current levels, with significant upside if Silevertinib succeeds. Read the full article on Seeking Alpha
Analysis Article • Jul 01

Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • May 04

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Mar 25

Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier

Summary Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net cash of $2.30 per share, presenting a major buying opportunity despite past shareholder losses. Aggressive selling by Biotech Growth N.V. caused recent price volatility, but this creates a buying opportunity given BDTX's strong fundamentals. I expect BDTX to reach $3.00 per share soon as the market absorbs the seller's shares and recognizes the partnership's value. Read the full article on Seeking Alpha
Seeking Alpha • Mar 13

Black Diamond Therapeutics: In Decline, But Why?

Summary Black Diamond Therapeutics, Inc. shows promising developments in its pipeline updates, highlighting significant advancements in targeted cancer therapies. The financial overview reveals a stable cash position, supporting ongoing research and development efforts without immediate capital concerns. Strengths include a robust pipeline and innovative approach, while risks involve clinical trial uncertainties and market competition. Bottom-line summary: Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech sector risks. Read the full article on Seeking Alpha
Seeking Alpha • Dec 30

Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts

Summary Black Diamond Therapeutics, Inc.'s BDTX-1535 showed a promising 42% ORR in Phase 2 trials for recurrent EGFR-mutant NSCLC, which addresses treatment-resistant mutations. The MasterKey platform enables targeting entire families of oncogenic mutations, offering potential solutions for underserved cancer populations like non-classical NSCLC and glioblastoma. BDTX’s $112.7 million cash reserves will support operations through Q2 2026. Restructuring efforts will prioritize high-value programs like BDTX-1535. Key milestones, including first-line NSCLC trial results and FDA feedback, are expected in Q1 2025, positioning BDTX-1535 for Phase 3 trials. At a P/B ratio of 1.3, BDTX trades at a discount compared to its sector, presenting a speculative “Buy” opportunity ahead of significant catalysts. Read the full article on Seeking Alpha
Analysis Article • Oct 30

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 08

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Summary Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from the phase 2 study using BDTX-1535 for the treatment of 2nd-line/3rd-line EGFRm NSCLC patients, expected in Q1 of 2025. Company to meet with the FDA in Q1 of 2025 and provide update on possible registration study to move BDTX-1535 program forward in the clinic. The global non-small cell lung cancer market is projected to reach $36.9 million by 2031. Read the full article on Seeking Alpha
Seeking Alpha • Jun 27

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Summary Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer. BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data readouts expected in 2024 and early 2025. Black Diamond Therapeutics has a strong-enough cash position for now, but the success of their pipeline candidates will be crucial for long-term sustainability. Read the full article on Seeking Alpha
Analysis Article • May 21

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, Black Diamond...
Analysis Article • Jan 31

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 12

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Summary Black Diamond Therapeutics is a precision oncology company targeting genetically defined cancers with its Masterkey approach. Besides NSCLC, BDTX also produced positive early data in recurrent GBM, a notoriously hard-to-treat disease. The company plans to initiate enrollments for expansion cohorts and seek FDA feedback for additional studies on various doses of BDTX-1535. Read the full article on Seeking Alpha
Analysis Article • Oct 26

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • May 05

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 16

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Oct 02

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Jul 02

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Revenue & Expenses Breakdown

How Black Diamond Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:BDTX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 260-431628
31 Mar 260-431630
31 Dec 2570221734
30 Sep 2570211640
30 Jun 2570142045
31 Mar 257052648
31 Dec 240-702751
30 Sep 240-732754
30 Jun 240-813058
31 Mar 240-802758
31 Dec 230-822759
30 Sep 230-842959
30 Jun 230-832758
31 Mar 230-872761
31 Dec 220-912864
30 Sep 220-962869
30 Jun 220-1092981
31 Mar 220-1213092
31 Dec 210-1263097
30 Sep 210-1222995
30 Jun 210-1052780
31 Mar 210-852464
31 Dec 200-672148
30 Sep 200-551938
30 Jun 200-461631
31 Mar 200-441226
31 Dec 190-35822
30 Sep 190-28517
30 Jun 190-22413
31 Mar 190-1128
31 Dec 180-927

Quality Earnings: BDTX is currently unprofitable.

Growing Profit Margin: BDTX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BDTX is unprofitable, but has reduced losses over the past 5 years at a rate of 34.3% per year.

Accelerating Growth: Unable to compare BDTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BDTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (64.6%).

Return on Equity

High ROE: BDTX has a negative Return on Equity (-44.29%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/17 01:06
End of Day Share Price 2026/08/17 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Black Diamond Therapeutics, Inc. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Arlinda LeeCanaccord Genuity
Ilya ZubkovFreedom Broker